Skip to main content
S 3781 116th Congress Senate Health Business records Drug safety, medical device, and laboratory regulation Emergency medical services and trauma care Government information and archives Health technology, devices, supplies Manufacturing Prescription drugs Public contracts and procurement Strategic materials and reserves Trade restrictions

PART Act

Introduced: May 20, 2020 Introduced by: Peters, Gary C. Democratic · Michigan See on congress.gov
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 20, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
May 20, 2020
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Pharmaceutical Accountability, Responsibility, and Transparency Act or the PART Act

This bill expands requirements for manufacturers of certain drugs and medical devices to report information to the Food and Drug Administration (FDA) and contains related provisions.

A manufacturer of a life-saving drug or medical device must notify the FDA of certain issues that may affect the drug or device's availability, such as an increase in demand that the manufacturer is likely unable to meet or an export restriction imposed by a foreign country where the drug or device is being manufactured. The manufacturer must notify the FDA within five days of becoming aware of the issue.

The bill also expands the types of foreign manufacturers of drugs and medical devices that must register with the FDA. Additionally, the bill expands a requirement for registered manufacturers to submit periodic reports to the FDA by (1) increasing the frequency of such reports, and (2) requiring the reports to include additional information about the amounts of drugs and medical devices being manufactured.

What's happening now May 20, 2020

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3781: PART Act. 116th Congress. Open America. https://openamerica.io/bill/116-S-3781/
MLA
"S. 3781: PART Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-3781/.
Bluebook (legal)
S. 3781, 116th Cong. (2026), https://openamerica.io/bill/116-S-3781/.
Markdown link
[S. 3781: PART Act](https://openamerica.io/bill/116-S-3781/)
Report a problem